Carney R M, Rich M W, teVelde A, Saini J, Clark K, Freedland K E
Am J Med. 1987 Aug;83(2):223-6. doi: 10.1016/0002-9343(87)90689-9.
Depression is believed to be a common side effect in patients receiving beta-blocker therapy. However, diagnoses of depression defined by current diagnostic criteria may not be more common in patients receiving beta-blockers than in patients with the same medical disorder receiving other medications. Seventy-seven patients undergoing elective cardiac catheterization for evaluation of chest pain received a semi-structured diagnostic psychiatric interview. Twenty-one percent of the patients receiving beta-blockers and 33 percent of the patients receiving medications other than beta-blockers met the current American Psychiatric Association criteria for major depressive disorder (DSM-III) (p = NS). The mean heart rate and state anxiety scores for patients taking beta-blockers were significantly lower than those measured in patients taking medications other than beta-blockers. No other medical or demographic differences were observed between the two groups. Despite the methodologic limitations of the study, there does not appear to be a difference in the point prevalence of depression between patients receiving beta-blockers and those receiving other medications.
抑郁症被认为是接受β受体阻滞剂治疗患者的常见副作用。然而，按照当前诊断标准诊断出的抑郁症在接受β受体阻滞剂治疗的患者中并不比患有相同疾病但接受其他药物治疗的患者更常见。77名因胸痛接受择期心导管插入术评估的患者接受了半结构化的诊断性精神科访谈。接受β受体阻滞剂治疗的患者中有21%，接受β受体阻滞剂以外药物治疗的患者中有33%符合美国精神病学协会目前的重度抑郁症诊断标准（《精神疾病诊断与统计手册》第三版）（p = 无显著差异）。服用β受体阻滞剂患者的平均心率和状态焦虑评分显著低于服用β受体阻滞剂以外药物的患者。两组之间未观察到其他医学或人口统计学差异。尽管该研究存在方法学上的局限性，但接受β受体阻滞剂治疗的患者与接受其他药物治疗的患者之间的抑郁症时点患病率似乎没有差异。
